BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of$ 1. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12%. A quarter ago, it was expected that this rare disease drug developer would post a loss of$ 1.09 per share when it actually produced a loss of $1.31, delivering a surprise of -20.18%.Over the last four quarters, the comp ...